Academic Journal
View in EDS

Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real‐World Retrospective Study

Bibliographic Details
Title: Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real‐World Retrospective Study
Authors: Rob, Filip, Hugo, Jan, Horažďovský, Jiří, Vantuchová, Yvetta, Čelakovská, Jarmila, Jarešová, Lucie, Policarová, Marie, Šternberský, Jan, Kojanová, Martina, Cetkovská, Petra, Thomová, Terézia, Sokolová, Kristýna, Finsterle, Jan, Janatová, Hana, Tomaško, Lenka, Čáková, Lenka, Tichý, Martin, Cetkovský, Martin, Nováková, Michaela
Contributors: Saleem, Suraiya
Source: Dermatologic Therapy ; volume 2025, issue 1 ; ISSN 1396-0296 1529-8019
Publisher Information: Wiley
Publication Year: 2025
Collection: Wiley Online Library (Open Access Articles via Crossref)
Description: Introduction: Janus kinase (JAK) inhibitors are novel therapies for atopic dermatitis (AD); however, only limited data exist on their effectiveness in patients with previous failures in biological treatment. Methods: Patients with moderate‐to‐severe AD and having completed a minimum of 16 weeks of JAK inhibitor therapy were divided into subgroups based on prior dupilumab exposure: those without prior exposure and those whose treatment was discontinued due to lack of efficacy (dupilumab nonresponders [DNR]). Eczema Area and Severity Index (EASI), DLQI, and Itch Numeric Rating Scale (Itch NRS) changes from baseline were assessed in Weeks 16 and 24 (when available). Adverse events during the follow‐up were recorded. Results: In total, 241 patients were included; 148 received upadacitinib (99 dupilumab‐naïve, 49 post‐dupilumab failure), 47 were with baricitinib (32 dupilumab‐naïve, 15 post‐dupilumab failure), and 46 received abrocitinib (35 dupilumab‐naïve, 11 post‐dupilumab failure). At Week 16, an EASI‐75 response in the upadacitinib group was achieved in 86% naïve versus 82% DNR patients, 91% naïve versus 73% DNR patients in the abrocitinib group, and 81% naïve versus 67% DNR in the baricitinib group. Itch NRS ≥ 4‐point reduction was achieved in 82% naïve versus 76% DNR patients on upadacitinib, 83% naïve versus 91% DNR patients on abrocitinib, and 72% naïve versus 40% DNR patients on baricitinib. Conclusion: In conclusion, our retrospective analysis suggests that previous dupilumab failure did not significantly affect the short‐term effectiveness of JAK inhibitor therapy for AD.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1155/dth/5548750
Availability: https://doi.org/10.1155/dth/5548750
https://onlinelibrary.wiley.com/doi/pdf/10.1155/dth/5548750
Rights: http://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.5D3D31CC
Database: BASE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://doi.org/10.1155/dth/5548750#
    Name: EDS - BASE (ns324271)
    Category: fullText
    Text: View record from BASE
Header DbId: edsbas
DbLabel: BASE
An: edsbas.5D3D31CC
RelevancyScore: 978
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 977.8095703125
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real‐World Retrospective Study
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rob%2C+Filip%22">Rob, Filip</searchLink><br /><searchLink fieldCode="AR" term="%22Hugo%2C+Jan%22">Hugo, Jan</searchLink><br /><searchLink fieldCode="AR" term="%22Horažďovský%2C+Jiří%22">Horažďovský, Jiří</searchLink><br /><searchLink fieldCode="AR" term="%22Vantuchová%2C+Yvetta%22">Vantuchová, Yvetta</searchLink><br /><searchLink fieldCode="AR" term="%22Čelakovská%2C+Jarmila%22">Čelakovská, Jarmila</searchLink><br /><searchLink fieldCode="AR" term="%22Jarešová%2C+Lucie%22">Jarešová, Lucie</searchLink><br /><searchLink fieldCode="AR" term="%22Policarová%2C+Marie%22">Policarová, Marie</searchLink><br /><searchLink fieldCode="AR" term="%22Šternberský%2C+Jan%22">Šternberský, Jan</searchLink><br /><searchLink fieldCode="AR" term="%22Kojanová%2C+Martina%22">Kojanová, Martina</searchLink><br /><searchLink fieldCode="AR" term="%22Cetkovská%2C+Petra%22">Cetkovská, Petra</searchLink><br /><searchLink fieldCode="AR" term="%22Thomová%2C+Terézia%22">Thomová, Terézia</searchLink><br /><searchLink fieldCode="AR" term="%22Sokolová%2C+Kristýna%22">Sokolová, Kristýna</searchLink><br /><searchLink fieldCode="AR" term="%22Finsterle%2C+Jan%22">Finsterle, Jan</searchLink><br /><searchLink fieldCode="AR" term="%22Janatová%2C+Hana%22">Janatová, Hana</searchLink><br /><searchLink fieldCode="AR" term="%22Tomaško%2C+Lenka%22">Tomaško, Lenka</searchLink><br /><searchLink fieldCode="AR" term="%22Čáková%2C+Lenka%22">Čáková, Lenka</searchLink><br /><searchLink fieldCode="AR" term="%22Tichý%2C+Martin%22">Tichý, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Cetkovský%2C+Martin%22">Cetkovský, Martin</searchLink><br /><searchLink fieldCode="AR" term="%22Nováková%2C+Michaela%22">Nováková, Michaela</searchLink>
– Name: Author
  Label: Contributors
  Group: Au
  Data: Saleem, Suraiya
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Dermatologic Therapy ; volume 2025, issue 1 ; ISSN 1396-0296 1529-8019
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Wiley
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2025
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: Wiley Online Library (Open Access Articles via Crossref)
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Introduction: Janus kinase (JAK) inhibitors are novel therapies for atopic dermatitis (AD); however, only limited data exist on their effectiveness in patients with previous failures in biological treatment. Methods: Patients with moderate‐to‐severe AD and having completed a minimum of 16 weeks of JAK inhibitor therapy were divided into subgroups based on prior dupilumab exposure: those without prior exposure and those whose treatment was discontinued due to lack of efficacy (dupilumab nonresponders [DNR]). Eczema Area and Severity Index (EASI), DLQI, and Itch Numeric Rating Scale (Itch NRS) changes from baseline were assessed in Weeks 16 and 24 (when available). Adverse events during the follow‐up were recorded. Results: In total, 241 patients were included; 148 received upadacitinib (99 dupilumab‐naïve, 49 post‐dupilumab failure), 47 were with baricitinib (32 dupilumab‐naïve, 15 post‐dupilumab failure), and 46 received abrocitinib (35 dupilumab‐naïve, 11 post‐dupilumab failure). At Week 16, an EASI‐75 response in the upadacitinib group was achieved in 86% naïve versus 82% DNR patients, 91% naïve versus 73% DNR patients in the abrocitinib group, and 81% naïve versus 67% DNR in the baricitinib group. Itch NRS ≥ 4‐point reduction was achieved in 82% naïve versus 76% DNR patients on upadacitinib, 83% naïve versus 91% DNR patients on abrocitinib, and 72% naïve versus 40% DNR patients on baricitinib. Conclusion: In conclusion, our retrospective analysis suggests that previous dupilumab failure did not significantly affect the short‐term effectiveness of JAK inhibitor therapy for AD.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article in journal/newspaper
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1155/dth/5548750
– Name: URL
  Label: Availability
  Group: URL
  Data: https://doi.org/10.1155/dth/5548750<br />https://onlinelibrary.wiley.com/doi/pdf/10.1155/dth/5548750
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: http://creativecommons.org/licenses/by/4.0/
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsbas.5D3D31CC
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.5D3D31CC
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1155/dth/5548750
    Languages:
      – Text: English
    Titles:
      – TitleFull: Effectiveness and Safety of JAK Inhibitors in Patients With Atopic Dermatitis Unresponsive Versus Naïve to Dupilumab: A Multicentric Real‐World Retrospective Study
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rob, Filip
      – PersonEntity:
          Name:
            NameFull: Hugo, Jan
      – PersonEntity:
          Name:
            NameFull: Horažďovský, Jiří
      – PersonEntity:
          Name:
            NameFull: Vantuchová, Yvetta
      – PersonEntity:
          Name:
            NameFull: Čelakovská, Jarmila
      – PersonEntity:
          Name:
            NameFull: Jarešová, Lucie
      – PersonEntity:
          Name:
            NameFull: Policarová, Marie
      – PersonEntity:
          Name:
            NameFull: Šternberský, Jan
      – PersonEntity:
          Name:
            NameFull: Kojanová, Martina
      – PersonEntity:
          Name:
            NameFull: Cetkovská, Petra
      – PersonEntity:
          Name:
            NameFull: Thomová, Terézia
      – PersonEntity:
          Name:
            NameFull: Sokolová, Kristýna
      – PersonEntity:
          Name:
            NameFull: Finsterle, Jan
      – PersonEntity:
          Name:
            NameFull: Janatová, Hana
      – PersonEntity:
          Name:
            NameFull: Tomaško, Lenka
      – PersonEntity:
          Name:
            NameFull: Čáková, Lenka
      – PersonEntity:
          Name:
            NameFull: Tichý, Martin
      – PersonEntity:
          Name:
            NameFull: Cetkovský, Martin
      – PersonEntity:
          Name:
            NameFull: Nováková, Michaela
      – PersonEntity:
          Name:
            NameFull: Saleem, Suraiya
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-locals
              Value: edsbas
            – Type: issn-locals
              Value: edsbas.oa
          Titles:
            – TitleFull: Dermatologic Therapy ; volume 2025, issue 1 ; ISSN 1396-0296 1529-8019
              Type: main
ResultId 1